Search

Your search keyword '"Scoccimarro, Erika"' showing total 21 results
Start Over Author "Scoccimarro, Erika" Publisher elsevier b.v.
21 results on '"Scoccimarro, Erika"'

1. Preoperative robotic radiosurgery for early breast cancer: Results of the phase II ROCK trial (NCT03520894)

Author

Meattini, Icro, Francolini, Giulio, Di Cataldo, Vanessa, Visani, Luca, Becherini, Carlotta, Scoccimarro, Erika, Salvestrini, Viola, Bellini, Chiara, Masi, Laura, Doro, Raffaela, Di Naro, Federica, Loi, Mauro, Salvatore, Giulia, Simontacchi, Gabriele, Greto, Daniela, Bernini, Marco, Nori, Jacopo, Orzalesi, Lorenzo, Bianchi, Simonetta, Mangoni, Monica, and Livi, Lorenzo

Published
2022
Full Text
View/download PDF

2. Local treatment for relapsing glioblastoma: A decision-making tree for choosing between reirradiation and second surgery

Author

Scoccianti, Silvia, Perna, Marco, Olmetto, Emanuela, Delli Paoli, Camilla, Terziani, Francesca, Ciccone, Lucia Pia, Detti, Beatrice, Greto, Daniela, Simontacchi, Gabriele, Grassi, Roberta, Scoccimarro, Erika, Bonomo, Pierluigi, Mangoni, Monica, Desideri, Isacco, Di Cataldo, Vanessa, Vernaleone, Marco, Casati, Marta, Pallotta, Stefania, and Livi, Lorenzo

Published
2021
Full Text
View/download PDF

4. 3089: LOCAL CONTROL AND LONG TERM TOXICITY IN SPINAL METASTASES TREATED WITH SRT

Author

Carnevale, Maria Grazia, Loi, Mauro, Simontacchi, Gabriele, Lorenzetti, Victoria, Greto, Daniela, Olmetto, Emanuela, Garlatti, Pietro, Meattini, Icro, Scoccimarro, Erika, Francolini, Giulio, Visani, Luca, DiCataldo, Vanessa, Salvestrini, Viola, Bonomo, Pierluigi, Peruzzi, Anna, Bettazzi, Beatrice, Valzano, Marianna, Casati, Marta, Arilli, Chiara, and Livi, Lorenzo

Published
2024
Full Text
View/download PDF

5. 2793: Clinical and toxicity outcomes with preoperative radiation therapy in a large cohort of STS patients

Author

Loi, Mauro, Greto, Daniela, Banini, Marco, Valzano, Marianna, Romei, Andrea, Morelli, Ilaria, Bonaparte, Ilaria, Simontacchi, Gabriele, Becherini, Carlotta, Scoccimarro, Erika, Francolini, Giulio, Salvestrini, Viola, Bonomo, Pierluigi, Peruzzi, Anna, Pallotta, Stefania, Roselli, Giuliana, Campanacci, Domenico, Guido, Scoccianti, Annarita, Palomba, Mangoni, Monica, Meattini, Icro, and Livi, Lorenzo

Published
2024
Full Text
View/download PDF

6. 2178: Role of ablative regimen and prior chemotherapy in liver metastases treated with SBRT

Author

Valzano, Marianna, Banini, Marco, Loi, Mauro, Bonomo, Pierluigi, Simontacchi, Gabriele, Galardi, Alessandra, Becherini, Carlotta, Greto, Daniela, Scoccimarro, Erika, Francolini, Giulio, Desideri, Isacco, Mangoni, Monica, Di Cataldo, Vanessa, Salvestrini, Viola, Mattioli, Chiara, Angelini, Lucia, Caprara, Luisa, Zani, Margherita, Marrazzo, Livia, Masi, Laura, Doro, Raffaella, and Livi, Lorenzo

Published
2024
Full Text
View/download PDF

7. 2105: Pregnancy in BRCA-carrier patients after breast cancer therapy: single-centre real-world experience

Author

Bettazzi, Beatrice, Visani, Luca, Gensini, Francesca, Olmetto, Emanuela, Garlatti, Pietro, Desideri, Isacco, Scoccimarro, Erika, Di Cataldo, Vanessa, Bonomo, Pierluigi, Peruzzi, Anna, Frosini, Giulio, Caprara, Luisa, Valzano, Marianna, Bernini, Marco, Orzalesi, Lorenzo, Nori, Jacopo, Bianchi, Simonetta, Becherini, Carlotta, Salvestrini, Viola, Livi, Lorenzo, and Meattini, Icro

Published
2024
Full Text
View/download PDF

8. 1442: EBUS-guided fiducial placement for SBRT in mediastinal nodal oligometastases

Author

Morelli, Ilaria, Dieng, Oulimata, Loi, Mauro, Simontacchi, Gabriele, Becherini, Carlotta, Greto, Daniela, Olmetto, Emanuela, Garlatti, Pietro, Meattini, Icro, Scoccimarro, Erika, Francolini, Giulio, Desideri, Isacco, Valzano, Marianna, Visani, Luca, Di Cataldo, Vanessa, Salvestrini, Viola, Luzzi, Valentina, Tomassetti, Sara, Doro, Raffaella, Masi, Laura, and Livi, Lorenzo

Published
2024
Full Text
View/download PDF

11. 2888: Safety of trastuzumab deruxtecan and radiation therapy in HER2-positive breast cancer patients

Author

Visani, Luca, Ratosa, Ivica, Ribnikar, Domen, Becherini, Carlotta, Bertini, Niccolò, Bonaparte, Ilaria, Stefanovski, Dimitar, Dobnikar, Nika, Desideri, Isacco, Olmetto, Emanuela, Mangoni, Monica, Di Cataldo, Vanessa, Peruzzi, Anna, Mattioli, Chiara, Cela, Doruntina, Valzano, Marianna, Salvestrini, Viola, Scoccimarro, Erika, Livi, Lorenzo, and Meattini, Icro

Published
2024
Full Text
View/download PDF

12. 1439: Comparing toxicity in soft tissue sarcoma: preoperative radio-chemotherapy vs radiotherapy alone

Author

Greto, Daniela, Loi, Mauro, Banini, Marco, Romei, Andrea, Morelli, Ilaria, Bonaparte, Ilaria, Campanacci, Domenico Andrea, Scoccianti, Guido, Roselli, Giuliana, Palomba, Annarita, Simontacchi, Gabriele, Becherini, Carlotta, Olmetto, Emanuela, Garlatti, Pietro, Meattini, Icro, Scoccimarro, Erika, Francolini, Giulio, Desideri, Isacco, and Livi, Lorenzo

Published
2024
Full Text
View/download PDF

15. Outcome and prognostic factors for older patients undergoing radiosurgery for brain metastases.

Author

Desideri, Isacco, Becherini, Carlotta, Visani, Luca, Stocchi, Giulia, Scoccimarro, Erika, Mariotti, Matteo, Salvestrini, Viola, Scoccianti, Silvia, Greto, Daniela, Bonomo, Pierluigi, Pecchioli, Guido, Bordi, Lorenzo, Della Puppa, Alessandro, Francolini, Giulio, Meattini, Icro, and Livi, Lorenzo

Abstract

Older patients with brain metastases (BM) are often excluded from clinical trials. The aim of our study was to investigate the outcomes following Gamma Knife radiosurgery (GKRS) in young old (65–74 years) and very old (≥75 years) patients with BM. Between October 2012 and October 2018, we treated 89 patients aged ≥65 years with GKRS. Patients were divided in two group: young old (YO) and very old (VO) patients. At baseline G8, Graded Prognostic Assessment (DS-GPA) and Basic Score for Brain Metastases (BSBM) were assessed for all patients. Survival analysis was estimated using the Kaplan-Meier (KM) method. Cox regression model was used to investigate the influence of significant factors on KM. Median age at the time of GKRS was 72.2 years (range 65–87). A mean of 2.52 lesions were treated per patient (range 1–14). Median overall survival (OS) for YO and VO patients was 14.2 and 15.7 months, respectively. At univariate analysis, there were no significant differences in OS between the two age groups. A high BSBM (p ≤.0001) and a high DS-GPA score (p =.0069) were associated with longer survival. A low DS-GPA score was the most powerful independent factor for predicting short survival (HR 1.76, 95% CI 1.25–2.46, p =.001) at multivariate analysis. GKRS is a safe approach to treat BM in elderly patients. DS-GPA score represents an important prognostic factor for survival in elderly patients undergoing GKRS. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

16. 2872: Predictors of pCR in Neoadjuvant Treatment for Locally Advanced Rectal Cancer.

Author

Bettazzi, Beatrice, Carnevale, Maria G., Loi, Mauro, Bonomo, Pierluigi, Galardi, Alessandra, Simontacchi, Gabriele, Becherini, Carlotta, Greto, Daniela, Scoccimarro, Erika, Francolini, Giulio, Desideri, Isacco, Mangoni, Monica, Di Cataldo, Vanessa, Salvestrini, Viola, Frosini, Giulio, Angelini, Lucia, Bertini, Niccolò, Banini, Marco, Talamonti, Cinzia, and Livi, Lorenzo

Subjects
*NEOADJUVANT chemotherapy, *RECTAL cancer
Published
2024
Full Text
View/download PDF

19. 1121: Examining clinical outcomes and toxicities in definitive chemoradiation for carcinoma of anal canal.

Author

Romei, Andrea, Galardi, Alessandra, Simontacchi, Gabriele, Becherini, Carlotta, Greto, Daniela, Olmetto, Emanuela, Garlatti, pietro, Scoccimarro, Erika, Visani, Luca, Bonomo, Pierluigi, Peruzzi, Anna, Meattini, Icro, Desideri, Isacco, Mangoni, Monica, Banini, Marco, Talamonti, Cinzia, and Livi, Lorenzo

Subjects
*ANUS, *TREATMENT effectiveness, *CHEMORADIOTHERAPY, *CARCINOMA
Published
2024
Full Text
View/download PDF

20. 1122: Chemotherapy regimens with definitive radiotherapy in Squamous Cell Carcinoma of the Anal Canal.

Author

Romei, Andrea, Lucidi, Sara, Greto, Daniela, Olmetto, Emanuela, Garlatti, Pietro, Meattini, Icro, Scoccimarro, Erika, Francolini, Giulio, Visani, Luca, Mangoni, Monica, Bonomo, Pierluigi, Loi, Mauro, Peruzzi, Anna, Frosini, Giulio, Cela, Dora, Bertini, Niccolò, and Livi, Lorenzo

Subjects
*ANUS, *SQUAMOUS cell carcinoma, *RADIOTHERAPY, *CANCER chemotherapy
Published
2024
Full Text
View/download PDF

21. Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer.

Author

Visani, Luca, Livi, Lorenzo, Ratosa, Ivica, Orazem, Miha, Ribnikar, Domen, Saieva, Calogero, Becherini, Carlotta, Salvestrini, Viola, Scoccimarro, Erika, Valzano, Marianna, Cerbai, Cecilia, Desideri, Isacco, Bernini, Marco, Orzalesi, Lorenzo, Nori, Jacopo, Bianchi, Simonetta, Morandi, Andrea, and Meattini, Icro

Subjects
*METASTATIC breast cancer, *CYCLIN-dependent kinase inhibitors, *EPIDERMAL growth factor receptors, *RADIOTHERAPY, *TERMINATION of treatment, *CYCLIN-dependent kinases
Abstract

• CDK4/6 inhibitors represent the standard-of-care for metastatic HR+/HER2 breast cancer. • Available data on CDK4/6 inhibitors and concomitant RT are conflicting. • We showed that concurrent RT did not increase treatments severe toxicity. • A consensus guideline to help physician's routine practice is strongly needed. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) currently represent the standard of care for the initial treatment of patients with metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. The aim of our study is to evaluate the safety of the use of concomitant radiation therapy (RT) in a consecutive series of HR+/HER2- patients treated in two academic institutions with CDK4/6i in the metastatic setting. From September 2017 to February 2020, we retrospectively collected and analysed data on a sequential series of patients treated with CDK4/6i, receiving RT or not, at two European institutions. Primary outcome of the study was the association between RT and any adverse events (AEs) ≥ G3. Secondary outcomes were the association between RT and any AEs (any grade), CDK4/6i dose reduction rate, and CDK4/6i treatment discontinuation rate. We analysed a total of 132 consecutive women; RT was prescribed in 57 (43.2%) patients (70 irradiated lesions). The median age of the series was 52.1 years (range 32.3–78.2). Concomitant RT administration was not significantly related to higher AEs ≥ G3 (p = 0.19) and any grade AEs (p = 1.0); there was no association with RT and CDK4/6i dose reduction (p = 0.49) and discontinuation rates (p = 0.14). At a median follow-up of 18.8 months, the progression-free survival (PFS) rate was 35% and the overall survival (OS) rate was 38.7% in the whole group. The use of concomitant RT did not affect both PFS (p = 0.71) and OS rates (p = 0.55). Our data are encouraging regarding the safety of this combination, showing that concurrent RT did not increase severe toxicity and did not have an impact on systemic treatment conduction. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results